The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review.
| Autor: | Prenggono MD; Division of Medical Oncology-Hematology, Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat/Ulin General Hospital, Banjarmasin., Yasmina A; Department of Pharmacology, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin., Ariyah M; Medical Education Study Program, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin., Wanahari TA; Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat/Ulin General Hospital, Banjarmasin, Indonesia., Hasrianti N; Department of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat/Ulin General Hospital, Banjarmasin, Indonesia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Oncology reviews [Oncol Rev] 2021 Nov 26; Vol. 15 (2), pp. 547. Date of Electronic Publication: 2021 Nov 26 (Print Publication: 2021). |
| DOI: | 10.4081/oncol.2021.547 |
| Abstrakt: | Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using 'chronic myeloid leukemia', 'tyrosine kinase inhibitors', 'imatinib', 'nilotinib', 'potassium', 'calcium', 'electrolytes' as keywords. This review used PubMed- MEDLINE, Cochrane Library, and Google Scholar as the source databases. Sixteen articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels range from the lower normal values to below normal values (hypocalcemia). Tyrosine kinase inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely plateletderived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of clinical signs and symptoms. Competing Interests: Conflict of interest: The authors declare no potential conflict of interest. (©Copyright: the Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|